Success Metrics

Clinical Success Rate
92.6%

Based on 25 completed trials

Completion Rate
93%(25/27)
Active Trials
3(8%)
Results Posted
48%(12 trials)
Terminated
2(5%)

Phase Distribution

Ph phase_1
8
21%
Ph phase_2
3
8%
Ph phase_4
10
26%
Ph early_phase_1
1
3%
Ph phase_3
10
26%
Ph not_applicable
5
13%

Phase Distribution

9

Early Stage

3

Mid Stage

20

Late Stage

Phase Distribution37 total trials
Early Phase 1First-in-human
1(2.7%)
Phase 1Safety & dosage
8(21.6%)
Phase 2Efficacy & side effects
3(8.1%)
Phase 3Large-scale testing
10(27.0%)
Phase 4Post-market surveillance
10(27.0%)
N/ANon-phased studies
5(13.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.2%

25 of 29 finished

Non-Completion Rate

13.8%

4 ended early

Currently Active

3

trials recruiting

Total Trials

39

all time

Status Distribution
Active(3)
Completed(25)
Terminated(4)
Other(7)

Detailed Status

Completed25
unknown7
Recruiting3
Withdrawn2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
39
Active
3
Success Rate
92.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.7%)
Phase 18 (21.6%)
Phase 23 (8.1%)
Phase 310 (27.0%)
Phase 410 (27.0%)
N/A5 (13.5%)

Trials by Status

unknown718%
recruiting38%
withdrawn25%
completed2564%
terminated25%

Recent Activity

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more
NCT07226141Phase 1

Valproate for the Treatment of Residual Amblyopia

Recruiting
NCT06929273Phase 3

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Recruiting
NCT05431595Phase 2

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Recruiting
NCT06089356Phase 4

Zolmitriptane as Prophylaxis for Chilhood Migraine

Unknown
NCT04513314Phase 4

Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium

Withdrawn
NCT02899611Phase 1

A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures

Completed
NCT05181007Phase 1

Drug-drug Interaction Between Ciprofol and Mefanamic Acid or Valproate

Completed
NCT00484471Phase 4

ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness

Completed
NCT03940326Phase 4

Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures

Completed
NCT04191863

Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.

Completed
NCT00167934Not Applicable

Determining Metabolic Effects of Valproate and Antipsychotic Therapy

Completed
NCT03025906Phase 2

Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus

Unknown
NCT01267864Phase 4

Valproate Versus Ketorolac Versus Metoclopramide

Completed
NCT01622439Phase 1

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Completed
NCT01543139Phase 2

Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression

Withdrawn
NCT00774306Not Applicable

Antiepileptic Drugs and Vascular Risk Markers

Terminated
NCT03235531Phase 4

Assessment of Valproate on Ethanol Withdrawal

Unknown
NCT01463111Not Applicable

Decision-Making in Bipolar Disorder

Completed
NCT02648633Phase 1

Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

Terminated
NCT02144623Early Phase 1

Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
39